Charles V Pollack
Overview
Explore the profile of Charles V Pollack including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
44
Citations
596
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kreitzer N, Albert N, Amin A, Beavers C, Becker R, Fonarow G, et al.
Cardiorenal Med
. 2025 Jan;
15(1):133-152.
PMID: 39809248
Background: Hyperkalemia, generally defined as serum potassium levels greater than 5.0 mEq/L, poses significant clinical risks, including cardiac toxicity and muscle weakness. Its prevalence and severity increase in patients with...
2.
Freiermuth C, Foster J, Manandhar P, Arulraja E, Erkanli A, Pollack C, et al.
West J Emerg Med
. 2024 Dec;
25(6):875-882.
PMID: 39625757
Introduction: Pain is a major driver of visits to the emergency department (ED). Clinicians must consider not only the efficacy of treatment options but also subsequent healthcare utilization and patient-centered...
3.
Mendenhall G, Jones M, Pollack C, Eoyang G, Silber S, Kennedy A
Cardiovasc Digit Health J
. 2024 Feb;
5(1):8-14.
PMID: 38390583
Background: The availability of portable and wearable electrocardiographic (ECG) devices has increased secondary to technological development. Single-lead ECG recordings have been shown to reliably detect and characterize cardiac rhythms such...
4.
Bhatt D, Pollack C, Mazer C, Angiolillo D, Steg P, James S, et al.
NEJM Evid
. 2024 Feb;
1(3):EVIDoa2100047.
PMID: 38319214
BACKGROUND: Ticagrelor is a reversible oral P2Y12 platelet inhibitor used to treat patients with acute coronary syndromes, prior myocardial infarction, high-risk coronary artery disease, transient ischemic attack, or ischemic stroke....
5.
Popovic B, Ducrocq G, Elbez Y, Bode C, Mehta S, Pollack C, et al.
Am J Cardiol
. 2022 Dec;
188:95-101.
PMID: 36493607
In patients with non-ST-elevation myocardial infarction (NSTEMI), total occlusion of the culprit coronary artery (OCA) is not uncommon. We sought to determine the frequency and clinical impact of OCA at...
6.
Abtan J, Wiviott S, Sorbets E, Popovic B, Elbez Y, Mehta S, et al.
Arch Cardiovasc Dis
. 2021 Feb;
114(3):187-196.
PMID: 33518473
Background: Few data are available on procedural complications of percutaneous coronary intervention (PCI) in the setting of acute coronary syndrome in the contemporary era. Aim: We sought to describe the...
7.
Milling T, Pollack C
Am J Emerg Med
. 2020 Aug;
38(9):1890-1903.
PMID: 32750627
Anticoagulation is key to the treatment/prevention of thromboembolic events. The primary complication of anticoagulation is serious or life-threatening hemorrhage, which may necessitate prompt anticoagulation reversal; this could also be required...
8.
Pollack C, Amin A, Wang T, Deitelzweig S, Cohen M, Slattery D, et al.
Hosp Pract (1995)
. 2019 Dec;
48(1):1-11.
PMID: 31815570
Non-ST-segment elevation myocardial infarction (NSTEMI) is defined as elevated cardiac biomarkers of necrosis in the absence of persistent ST-segment elevation in the setting of anginal symptoms or other acute event....
9.
Eikelboom J, van Ryn J, Reilly P, Hylek E, Elsaesser A, Glund S, et al.
J Am Coll Cardiol
. 2019 Oct;
74(14):1760-1768.
PMID: 31582135
Background: Dabigatran and idarucizumab, its reversal agent, are renally cleared. Objectives: The purpose of this study was to determine the extent of reversal and outcomes according to baseline renal function...
10.
Bhatt D, Pollack C, Weitz J
N Engl J Med
. 2019 Aug;
381(6):586.
PMID: 31390508
No abstract available.